NIH Awards Linshom Medical $3.5M for Respiratory Monitoring Trial

On November 5, 2026, Linshom Medical, Inc. received a $3.5 million Small Business Innovation Research (SBIR) Phase 2B grant from the National Institutes of Health (NIH) and the National Heart, Lung, and Blood Institute (NHLBI). The funding supports development of a wireless, portable system for continuous respiratory monitoring and a multi-center clinical trial. The project combines technology development with clinical evidence generation, connecting the device’s monitoring capabilities to an assessment of whether earlier detection and intervention can improve outcomes and produce measurable economic benefits.

The planned trial builds on prior work at Ohio State Wexner Medical Center (OSU). Linshom Medical Chief Executive Officer Richard Hughen said, “A previous study at Ohio State Wexner Medical Center (OSU) proved the early detection capability of the Linshom Medical sensor, providing health care providers time to intervene before a crisis develops. Now, with the new clinical trial, we aim to quantify the medical-economic benefits of early detection and early intervention.” The new study’s stated objective therefore extends beyond demonstrating that the sensor detects respiratory changes: it is intended to evaluate the value of acting on that information earlier.

For government contractors and prospective partners, this is a funded project, not an open solicitation. The award does not itself establish a procurement opportunity or announce a contract competition. However, the scope may be relevant to medical-device engineering firms, clinical research organizations, and other organizations whose capabilities align with wireless monitoring, device development, multi-center trial execution, or evidence assessment. Companies should distinguish potential subcontracting or collaboration interest from a publicly available federal bid; the source does not identify specific partner requirements, procurement timelines, or additional awards.

The project also reflects federal investment in patient-monitoring technology and in generating evidence about the consequences of earlier clinical intervention. Its medical-economic focus may interest organizations that develop or evaluate respiratory monitoring systems for healthcare settings, particularly those able to support clinical validation or analyze the relationship between detection, intervention, and costs. GovCon teams tracking NIH and NHLBI health-technology funding can use the award as an indicator of agency support for development paired with clinical evaluation, while avoiding assumptions about future contracting actions that have not been announced.

• Award amount: Linshom Medical received a $3.5 million NIH/NHLBI SBIR Phase 2B grant on November 5, 2026.
• Funding agencies: The award is associated with the National Institutes of Health and the National Heart, Lung, and Blood Institute.
• Development scope: Funding supports wireless, portable, continuous respiratory monitoring technology.
• Clinical scope: The project includes a multi-center clinical trial to assess the medical-economic benefits of earlier detection and intervention.
• Prior evidence: The company cites an earlier study at Ohio State Wexner Medical Center (OSU) that demonstrated the sensor’s early-detection capability.
• Company objective: CEO Richard Hughen says the new trial aims to quantify the medical-economic benefits of early detection and early intervention.
• Potential partner relevance: Medical-device contractors, engineering firms, and clinical research organizations may assess alignment with the development and trial work.
• Procurement status: This is a funded grant project, not an open solicitation; no specific contract opportunity or partner requirement is identified in the source.
• Market signal: The award indicates federal investment in patient-monitoring technology and evidence generation tied to earlier clinical intervention.